Adial Pharmaceuticals
Yahoo Finance • last month
Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04
FDA feedback confirms Adial’s proposed in vitro bridging strategy to the Phase 3 formulation to fulfill the bridging requirement for the 505(b)(2) regulatory registration pathway for approval Adial moves forward with manufacturing of clin... Full story
Yahoo Finance • 2 months ago
Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies
New Patent covers claims which focus on method for identifying genetic markers in patients with alcohol or opioid related disorders Patent expands the identification of potential treatment candidates for AD04 administration based on the p... Full story
Yahoo Finance • 2 months ago
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders
GLEN ALLEN, Va., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addi... Full story
Yahoo Finance • 2 months ago
Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Completion enables the End-of-Phase 2 (EOP2) interaction with the FDA on the design of the Phase 3 program and is expected to facilitate ongoing partnership discussions Adial’s formulation exhibited predictable bioavailability relative to... Full story
Yahoo Finance • last year
Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar
CHARLOTTESVILLE, Va., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of... Full story
Yahoo Finance • last year
Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
CHARLOTTESVILLE, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of... Full story
Yahoo Finance • last year
Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
CHARLOTTESVILLE, Va., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of... Full story
Yahoo Finance • 2 years ago
Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder
Pre-registration for the LinkedIn Live event will begin on Thursday, September 28th Industry experts to discuss the need for non-abstinence-based therapies in Alcohol Use Disorder (AUD) CHARLOTTESVILLE, Va., Sept. 28, 2023 (GLOBE NEWSW... Full story
Yahoo Finance • 2 years ago
Adial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering
CHARLOTTESVILLE, Va., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and preven... Full story
